Leukemia Innovations

Atypical continual myeloid leukemia is a sort of leukemia. It is a heterogeneous ailment belonging to the institution of myelodysplastic/myeloproliferative (MDS/MPN) syndromes. In aCML many clinical capabilities and laboratory abnormalities propose the prognosis of chronic myelogenous leukemia. However, the dearth of the pathognomonic Philadelphia chromosome and of the ensuing BCR-ABL1 fusion factor to an extraordinary pathogenetic process. Since no unique recurrent genomic or karyotypic abnormalities have been diagnosed in aCML, the molecular pathogenesis of this sickness has remained elusive and the final results dismal with no development over the last 20 years. This sharply contrasts with the final results for CML, for which the prognosis become dramatically advanced by way of the development of imatinib as a specific inhibitor of the BCR-ABL protein and especially for CML. Atypical persistent myeloid leukemia (aCML) presents more than one demanding situations for researchers and practitioners. Rare, aggressive, and sharing overlapping functions with myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN).

High Impact List of Articles

Relevant Topics in

Table of Contents

For Authors

For Librarians

Open Access Journals